6 results about "Retinol binding protein" patented technology

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The application provides a liquid chromatography analysis method for simultaneously detecting multiple proteins, which adopts anion liquid chromatography with non-porous resin as a stationary phase, a Tris gradient eluent phase containing Cl ‑ , the non-porous resin is bonded with a hydrophilic polymer nanolayer on the surface, the nanolayer is modified with a quaternary ammonium group, the proteins have different isoelectric points, and the pH of the eluent phase is greater than the isoelectric points of the proteins. The application can simultaneously separate and purify multiple proteins through one-time anion liquid chromatography, and can approximately achieve baseline separation. The overall method is simple, economical, efficient, and environmentally friendly for the mobile phase, and is suitable for the separation of proteins with different isoelectric points, and is particularly suitable for the detection and separation of proteins such as albumin, transferrin, retinol binding protein, beta 2 microglobulin and alpha 1 microglobulin in urine.

The present invention relates to a method for selecting a patient suffering from a stroke for reperfusion therapy, based on determining the levels of retinol binding protein 4 (RBP4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The present invention also relates to a method for differentiating between ischemic stroke and hemorrhagic stroke, and to a kit comprising reagents for performing said methods.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.

The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

The application provides a reagent for detecting RBP1 for preparing a kit for diagnosing atrial fibrillation, difference genes of atrial fibrillation patients and non-atrial fibrillation patients are obtained through weight gene co-expression network analysis (WGCNA), and RT-qPCR is used for verification in human peripheral blood samples. Peripheral blood leukocyte extraction: 3-5ml of venous blood is taken, EDTA anticoagulation is carried out, and centrifugation is carried out at 2500rpm for 10min; the upper plasma is carefully sucked and is divided into 3 0.5ml centrifuge tubes; 3 times the volume of hemolytic liquid is added into the blood cells, and shaking is carried out, ice bath is carried out for 15min; 2500rpm centrifugation is carried out for 10min, and the supernatant is discarded. The RBP1 detection method can be used as a biomarker to assist the diagnosis of atrial fibrillation. Retinol binding protein 1 is a protein encoded by the CRABP1 gene. It binds with high affinity to retinol and retinoids, protects retinoids from nonspecific oxidation, and delivers retinoids to specific enzymes. Changes in RBP1 gene expression will affect retinoic acid production, cell proliferation and microenvironment of epithelial cells. Blood biomarker sampling is simple and low in price.